MedTrace Logo

Pancreatic Islet Cell Transplantation

NCT00214786 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess a novel approach to immunosuppression in allogenic pancreatic islet cell transplant recipients. In addition, the study aims to assess remote site islet processing with culture for pancreatic islet cell transplantation in human subjects.

Conditions

Interventions

BIOLOGICAL

Islet cell transplantation

Allogenic islet transplantation

Sponsors & Collaborators

  • Baylor Health Care System

    collaborator OTHER

  • University of Miami

    collaborator OTHER

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • Marlon Levy, MD · Baylor Regional Transplant Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00214786 on ClinicalTrials.gov